Format

Send to

Choose Destination
Inflammation. 2016 Dec;39(6):1949-1959.

Therapeutic Effects of Resveratrol in a Mouse Model of LPS and Cigarette Smoke-Induced COPD.

Author information

1
School of Resources, Environmental & Chemical Engineering of Nanchang University, Nanchang, 330031, China.
2
Medical Experiment Education Department, Medical College of Nanchang University, Nanchang, 330031, China.
3
Department of Anesthesia, Wenzhou Central Hospital, Wenzhou, 325000, China.
4
Department of Neurology, Xiangyang Central Hospital, Xiangyang, 441000, China.
5
School of Resources, Environmental & Chemical Engineering of Nanchang University, Nanchang, 330031, China. sirlrp@163.com.

Abstract

This study was designed to examine whether resveratrol exerts the protective effects on LPS and cigarette smoke (LC)-induced COPD in a murine model. In lung histopathological studies, H&E, Masson's trichrome, and AB-PAS staining were performed. The cytokines (IL-6, IL-17, TGF-β, and TNF-α) and inflammatory cells in BALF were determined. The Beclin1 level in the lungs of mouse was analyzed. Compared with the LC-induced mouse, the level of inflammatory cytokines (IL-17, IL-6, TNF-α, and TGF-β) of the BALF in the resveratrol + cigarette smoke-treated mouse had obviously decreased. Histological examination of the lung tissue revealed that the resveratrol treatment attenuated the fibrotic response and mucus hypersecretion. In addition, resveratrol inhibited the expression of the Beclin1 protein in mouse lungs. The presented findings collectively suggest that resveratrol has a therapeutic effect on mouse LC-induced COPD, and its mechanism of action might be related to reducing the production of the Beclin1 protein.

KEYWORDS:

COPD; beclin1; mucus hypersecretion; resveratrol

PMID:
27590234
DOI:
10.1007/s10753-016-0430-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center